YOU ARE CORDIALLY INVITED TO

Life Science Under the Radar Day

WHAT? Innovation Services in collaboration with Biotech Start-Up Management Ltd is arranging a day from partnering opportunities. We have invited representatives from industry (pharma, diagnostics, medtech, biotech), venture capitalists (VCs) and business incubators to meet our researchers having commercially interesting projects.

Currently following organizations are participating: AIESEC, Arctic Crossing Consulting, Business Oulu, Butterfly Ventures, CD3 (Centre for Drug Design and Discovery), Ginolis, Janssen, Pharmaceutical companies of Johnson and Johnson, JouZeNet Consulting, Technopolis, Turku Science Park, USBIMED

We have preselected 9 projects which will be presented in the event (descriptions below). But also you have now an opportunity to network and learn how to present your ideas to industry/VCs.

WHEN? Fri 29th April 2016 at 12 – 6 pm

WHERE? TellUs Innovation Arena, Ice Breaker Stage, Linnanmaa campus

REGISTRATION:

at latest 20th April 2016 to address:
https://link.webropolsurveys.com/S/8B8D7AAA7A5446C1

AIM: To academics – opportunity to network, find collaborators, get feedback from the relevance of your research project

To industry – find new inventions, know-how and collaboration

PROGRAM:

- 12 - 3 pm: Short preselected pitches
- 3 - 6 pm: Get Together Event with refreshments and snacks

MORE INFORMATION: Maarit.Jokela@oulu.fi, tel. +358-40 355 9660

UNIVERSITY OF OULU

THE SHORT DESCRIPTION OF THE UPCOMING PRESENTATIONS:

1) ARTD10. *Small molecule, cancer, structural biology*

A new class of small molecule inhibitors with selectivity towards human mono ADP-ribosylating enzymes can affect multiple disease relevant cell signalling pathways. A compound with ARTD10 specificity sensitizes cancer cells to DNA damage reveals the first potential therapeutic applications for the molecules in cancer treatment.

2) BIO IN. *Biosensor, insulin, saliva.*

We have developed a fast method to analyze saliva's insulin concentration. This method is preventative and aims to prevent onset of type 2 diabetes by offering an easy-to-use self-monitoring devise. Our target group is all persons in risk of having type 2 diabetes including overweight and obese people.

3) BrainICU. *Brain function, intensive care.*

We have developed a new ground breaking technology for assessing patient's brain function during intensive care. Our novel approach combines EEG-measurement with common pharmacological compounds and clinical procedures to empower physicians with the first truly objective and practical measurement of brain function. This unique solution offers reliable diagnostic and prognostic information that is expected to lead to significant improvements in both the quality of care and the costs involved in providing that care.

4) CHAIN. *Antibiotics, small peptides.*

There is scarcity of antibiotics for gram negatives and we have developed highly potential antimicrobial peptides with broad and narrow spectrum of activity against various clinical strains of Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa. The lead antimicrobial peptides are small compound of 11-16 amino acids with beta-sheet stable structure and have comparable antimicrobial activity with Gentamicin. These peptides have also antifungal activity.

5) CIRCADIAN. *Optical, monitoring, circadian cycle, drug testing*.

Monitoring cellular processes regulated by a circadian cycle in a humidified cell culture incubator is challenging and requires continuous real time monitoring. The difficult environmental conditions of the incubators have limited the usability of technologies allowing real time measurements. We want to overcome these limitations by a fiber optic based luminescence detection system allowing to measure circadian cycles inside an incubator.

6) FAR. *AMD, fatty acids analog.*

There is no effective treatment for age-related macular degeneration (dry AMD) is the leading cause of registered blindness among the elderly, affecting over 30 million people worldwide. We have discovered in our research fatty acid analogs which have significant antioxidant activity and are developed as a treatment against retinal degeneration.

7) MyoGel. *Drug testing, 3D cell culture, invasion.*

MyoGel is a 3D cell culture matrix enabling fast testing of drug compounds. As human tissue based material it resembles real life conditions in human body improving predictability of preclinical drug testing, resulting in cost savings and avoidance of unnecessary use of test animals.

8) SeeMIK. *Medical imaging, interpretation* (http://seemik.com).

Our tool helps and assists radiologist in the interpretation and diagnosing of medical images. It enables fast search by image, or even more detailed point of interest (radiological finding) and/ or text of similar cases safely from hospital's own databases reducing time used to find information through text search from external sources.

9) VitD. *Arthritis*, *vitamin D.*

We have found that biologically active vitamin D and its analog inhibit synovial cell growth and cytokine secretion in vitro proposing that could be used as a novel locally deliverable treatment reagent in patients with rheumatoid arthritis.